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Background: Atopic dermatitis (AD) is characterized by skin barrier dysfunction. Few studies have used
noninvasive techniques to measure epidermis function in asymptomatic neonates.
Methods: Data of 116 infants from our previous randomized controlled study were analyzed. Skin barrier
function was measured through transepidermal water loss (TEWL), stratum corneum hydration (SCH),
and pH. The association between skin barrier function and time to AD development was evaluated.
Patients were classiﬁed with high or low TEWL, and SCH and pH were assessed. The survival function of
the time to AD development and hazard ratios were estimated. Allergic sensitization to egg white and
ovomucoid at 32 weeks was assessed.
Results: Regardless of a ﬁlaggrin mutation, TEWL (optimal cutoff, 6.5 g/m2/h) of the forehead within the
ﬁrst week of life showed a lower p-value than TEWL of the leg, and the SCH and pH measurements.
Baseline TEWL of the forehead was not different between groups, except for the mean gestational age,
and it was not affected by humidity. We found a signiﬁcant difference in the cumulative AD incidence
between the high and low TEWL groups for the forehead only (p < 0.05). The probability without AD was
lower in the high TEWL group than in the low TEWL group. For only the high TEWL group, AD devel-
opment decreased signiﬁcantly with daily emollient use. The high TEWL group exhibited a higher rate of
sensitization to ovomucoid (p ¼ 0.07).
Conclusions: TEWL of the forehead during the ﬁrst week of life is associated with AD development.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atopic dermatitis (AD) is a chronic inﬂammatory skin disorder




rgology. Production and hosting by Elseinfancy is thought to contribute to the development of subsequent
allergies, also known as atopic march.2,3
A family history of AD and being a carrier for a ﬁlaggrin (FLG)
gene mutation are risk factors for AD, bronchial asthma, and food
allergies.4e6 FLG is a keratin-aggregating protein and plays a major
role in the function of the epidermis.5,6 Previous studies have
indicated that allergy development may be associated with a
damaged epidermal barrier.7
In recent years, noninvasive skin assessment strategies such as
measurements of transepidermal water loss (TEWL), stratumvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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fants.8,9 FLG mutations are associated with increased TEWL, which
reﬂects skin barrier dysfunction.10 Moreover, a recent study by
Kelleher et al. showed that increased TEWL on the forearm at 2 days
and 2 months of age predicted AD development at 1-year-old.11
Although several studies using noninvasive skin assessment ap-
proaches measuring TEWL, SCH, or pH in infants successfully
analyzed skin barrier function,8,9 Kelleher et al.'s study only used
TEWL measurements on the forearm.11 Skin barrier function values
differ by different body areas12; thus, it is possible that the same
measurement method reveals different results depending on
where the measurement is performed. Moreover, although a cor-
relation between the FLG mutation and allergic sensitization was
reported,13,14 it is unclear if skin barrier function in neonates pre-
dicts sensitization to food allergens.
We previously reported the ﬁndings of a randomized controlled
parallel-group study that indicated that the daily application of
emollients in neonates reduced AD risk until 32 weeks of life.15 In
this study, we performed a retrospective post-hoc analysis of the
dataset of the same participants. We assessed whether measuring
skin function during the neonates' ﬁrst week of life using several
noninvasive skin function tests (TEWL, SCH, and pH) could predict
AD development. Furthermore, we determined whether increased
TEWL within the ﬁrst week of life predicted a risk of increased
sensitization to egg white and ovomucoid at age 32 weeks.
Methods
Participants and study design
Weperformed a retrospective post-hoc analysis of prospectively
collected data from our previous trial.15 A total of 116 neonates with
a high risk of developing AD, as measured by noninvasive skin
measurement techniques within the ﬁrst 7 days of life, were
analyzed. Skin barrier function was measured through TEWL, SCH,
and pH. Written informed consent was obtained from the infants'
parents before delivery. Our study was approved by the institu-
tional review board of the National Center for Child Health and
Development (NCCHD).
Atopic dermatitis diagnosis and skin barrier function measurement
AD was diagnosed by the same blinded dermatologist during
the participants' scheduled visits, according to the criteria estab-
lished in our previous trial.15 Skin barrier function was tested in
neonates within the ﬁrst 7 days of life (mean ± standard deviation
[SD], 3.24 ± 1.37 days). The following noninvasive devices were
used: Vapo Meter, SW-4002 (Delﬁn Technologies, Kuopio, Finland)
for TEWL, Moisture Meter, SC-5 (Delﬁn Technologies) for SCH, and
Skin-pH-Meter PH905 (Courage & Khazaka Electronic GmbH, K€oln,
Germany) for pH. The TEWL and SCH values were measured on the
outer side of the lower leg and the forehead, and pH was measured
on the cheek. We calculated the median value of three repeated
measurements. All measurements were conducted while neonates
were resting and not crying, and before any emollients were
applied. The room temperature was maintained between 24 C and
27 C, and humidity ranged between 11% and 58% (mean ± SD,
38.9 ± 8.31%).
Assessment of food allergen sensitization
Serum egg white- and ovomucoid-speciﬁc immunoglobulin E
(IgE) levels were measured by using a diamond-like carbon chip
with high-density allergen immobilization and high sensitivity.16,17
After conﬁrming the correlation between the datasets, speciﬁc IgEvalues were converted to CAP-FEIA equivalents.15,16 The cutoff
levels for allergic sensitization were set at 0.35 or 0.70 kUA/L CAP-
FEIA equivalents.
Filaggrin mutation analysis
The primer sets for the representative FLG gene mutations
found in the Japanese population with AD (p.R501*, p.S2889*,
p.S3296*, c.3321delA, p.Q1701*, p.S2554*, and p.K4022*) were
used. FLG mutations were genotyped using TaqMan analysis (Life
Technologies, Thermo Fisher Scientiﬁc, Waltham, MA, USA), as
described previously.6,15,18
Statistical analyses
We used log-rank tests to determine the cut-off points of the
skin test (TEWL, SCH, and pH) values measured within the ﬁrst
week of life to evaluate the time to AD development until 32 weeks.
Data derived from the skin tests were converted to binary data,
allowing us to classify neonates with high or low values, based on
an entire series of cutoff values. The cutoff value providing the
minimum p-value was considered as the best cutoff value for each
test. After determining the cutoff values to classify patients with
high or low values, the survival function of the time to AD devel-
opment was estimated by the KaplaneMeier method, and the
hazard ratio (HR) was estimated by a Cox regression model to
assess the association between the skin tests and AD development.
Moreover, univariate comparisons were conducted using the chi-
square and ManneWhitney U tests, as appropriate. In addition,
groups were further subdivided into two groups based on the use of
emollients (daily vs. as needed). SPSS for Windows (version 18.0;
SPSS Inc.; Chicago, IL, USA) and the R software (version 3.1.2, http://
www.R-project.org) were used for statistical analyses, and p < 0.05
was regarded as statistically signiﬁcant.
Results
In our previous randomized controlled trial,15118 neonates were
recruited at the NCCHD (Tokyo, Japan) within 7 days of birth from
November 2010 to November 2013. These infants were randomly
allocated to two groups: an intervention group receiving daily
emollient applications, and a control group receiving emollient
applications as needed during the ﬁrst 32 weeks of life. Signiﬁ-
cantly fewer infants who received daily emollient applications
developed AD than those who received emollient applications as
needed. In this post-hoc study, we analyzed data of 116 infants (58
and 58 in the intervention and control group respectively;
Supplementary Table 1). One infant was excluded because skin
function was not measured by noninvasive devices within the ﬁrst
week of life, and another infant was withdrawn from the study
before the skin function examination could be conducted because
of a hemangioma.
The log-rank test for TEWL, SCH, and pH values within the ﬁrst
week of life and cumulative AD incidence rates at age 32 weeks
showed that TEWL measurements on the forehead were more
useful than the other methods (Fig. 1). Thus, only these measure-
ments were used for further analyses. Participants were then
divided into two groups: high TEWL (TEWL 6.50 g/m2/h; n ¼ 71)
and low TEWL (TEWL <6.50 g/m2/h; n ¼ 45). Besides the mean
gestational age, we did not observe any difference in baseline pa-
rameters between groups (Table 1).
The log-rank test showed signiﬁcant differences in cumulative
AD incidences between the high and low TEWL groups (p < 0.05,
log-rank test; HR: 2.00; 95% conﬁdence interval [CI]: 1.05e3.80;
























































































Fig. 1. Correlation between noninvasive skin measurement results and AD development by age 32 weeks. Using the log-rank test, we calculated the p-values for all skin barrier
function values measured via transepidermal water loss (TEWL), stratum corneum hydration (SCH), and pH, and the cumulative AD incidence rates at age 32 weeks. A, TEWL on the
lower leg, 5.0e11.7 g/m2/h; B, TEWL on the forehead, 4.9e10.7 g/m2/h; C, SCH on the lower leg, 8.0e22.0 AU [arbitrary units]; D, SCH on the forehead, 8.0e30.0 AU; and E, pH on the
cheek, 5.1e6.1. The measurements show a signiﬁcant difference in TEWL measured on the forehead (6.4, 6.5, 6.7, 6.9, 7.8, 7.9, and 8.9 g/m2/h), SCH on the lower leg (15 AU), and SCH
on the forehead (21 AU). TEWL measured on the forehead within the ﬁrst 7 days of life shows a stronger and more statistically signiﬁcant correlation with cumulative AD incidence
by age 32 weeks than SCH and pH (dashed line, p ¼ 0.05). Based on the results of the log-rank test, the optimal cutoff value for TEWL measured on the forehead is 6.50 g/m2/h. AD,
atopic dermatitis; AU, arbitrary units.
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risk for developing AD over time between infants in the high and
low TEWL groups (p < 0.05, log-rank test; HR: 2.65; 95% CI:
1.16e6.06; Fig. 3A). In contrast, no signiﬁcant difference between
the high and low TEWL groups was seen in the intervention group
(in which emollients were applied to all infants daily) (p ¼ 0.368,
log-rank test; HR: 1.60, 95% CI: 0.57e4.49; Fig. 3B). For only the low
TEWL group, the log-rank test did not show a signiﬁcant difference
in the cumulative AD incidence between daily emollients and the as
needed groups (data not shown).
Lastly, we evaluated the rate of infants that developed allergic
sensitization to egg white and ovomucoid in the high and low
TEWL groups (using IgE cutoff levels of 0.35 and0.70 kUA/L). No
signiﬁcant differences were observed for allergic sensitization to
egg white; however, a higher rate of ovomucoid sensitization was
seen in the high TEWL group when compared to the low TEWL
group (p ¼ 0.07 and p ¼ 0.13 for cutoff levels of 0.35 kUA/L and
0.70 kUA/L, respectively; chi-square test; Table 2). The rate of egg
white and ovomucoid sensitization between the daily application
with emollients and as needed groups was not signiﬁcantly
different (data not shown).Discussion
To the best of our knowledge, this is the ﬁrst report to show that
TEWL is superior to other noninvasive skin measurements in pre-
dicting the development of AD in early infancy. Our study also
showed that the daily use of emollients in infants with barrier
dysfunction, as estimated by an increased TEWL on the forehead,
was associated with a signiﬁcantly lower risk of developing AD.
Asymptomatic infants with increased TEWL in the ﬁrst week of life
were more likely to develop subsequent sensitization to ovomu-
coid, although this difference was not statistically signiﬁcant.
Individuals with elevated TEWL are often carriers of FLG muta-
tions.10 TEWL is deﬁned as the insensible water depletion from
inside the body via the epidermal layer, which reﬂects skin barrier
function.19 Meanwhile, although an FLG null mutation, which is
associated with epidermal barrier dysfunction, is a risk factor for
AD,10 approximately 54% of FLG null mutation carriers in the United
States have never developed AD symptoms.20 Proﬁlaggrin, the
precursor of FLGmonomers, is cleaved by proteolysis enzymes (e.g.,
bleomycin hydrolase [BLMH], calpain-1, and caspase-14) and pro-
cessed into matured FLG.21 BLMH downregulation has been shown
Table 1
Patients' characteristics.
High TEWL group Low TEWL group p-value
(n ¼ 71) (n ¼ 45)
Intervention, no. (%) 36/71 (50.7) 22/45 (48.9) NS
Sex (female), no. (%) 31/71 (43.7) 19/45 (42.2) NS
Mean age of mothers
at delivery (y)
35.3 ± 5.09 35.5 ± 4.48 NS
Cesarean section, no. (%) 14/71 (19.7) 14/45 (31.1) NS
Mean gestational age (wk) 39.3 ± 0.96 38.8 ± 1.0 <0.01
Mean birth weight (g) 3004 ± 356 3129 ± 374 NS
Breastfeeding at age
1 month, no. (%)
33/70z (47.1) 23/44z (52.3) NS
Mean no. of siblings 0.29 ± 0.52 0.47 ± 0.69 NS
Born in autumn, no. (%)y 21/71 (29.6) 16/45 (35.6) NS
Family history
Food allergy, no. (%) 27/71 (38.0) 17/45 (37.8) NS
Bronchial asthma, no. (%) 23/71 (32.4) 21/45 (46.7) NS
Allergic rhinitis, no. (%) 57/71 (80.3) 35/45 (77.8) NS
Environmental exposures
Smoking in the family,
no. (%)z
10/69 (14.5) 7/45 (15.6) NS
Pets, no. (%)z 15/70 (21.4) 9/45 (39.1) NS
Dog, no. (%) 8/70 (11.4) 5/45 (11.1) NS
Cat, no. (%) 4/70 (5.7) 2/45 (4.4) NS
FLG mutation, no. (%)z 4/34 (10.8) 3/26 (11.5) NS
p.R501* 0/34 (0.0) 0/26 (0.0) NS
p.S2889* 1/34 (2.9) 1/26 (3.8) NS
p.S3296* 1/34 (2.9) 0/26 (0.0) NS
c.3321delA 1/34 (2.9) 1/26 (3.8) NS
p.Q1701* 1/34 (2.9) 0/26 (0.0) NS
p.S2554 0/34 (0.0) 1/26 (3.8) NS
p.K4022* 0/34 (0.0) 0/26 (0.0) NS
No., number; NS, not signiﬁcant; TEWL, transepidermal water loss; wk, week; y,
years.
* Nonsense mutation according to nomenclature for the description of sequence
variants in Human Genome Variation Society.
y Autumn was deﬁned as October to December.
z We were not able to acquire all data.
Fig. 2. KaplaneMeier curves for AD development by age 32 weeks. The probability of
AD incidence stratiﬁed by TEWL (measured on the forehead) is shown. The high TEWL
group (TEWL 6.50 g/m2/h) shows a higher AD incidence than the low TEWL group
(TEWL <6.50 g/m2/h) (log-rank test, p ¼ 0.031). AD, atopic dermatitis; TEWL, trans-
epidermal water loss.
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epidermis of AD subjects.22 This indicates that although FLG is a key
protein related to epidermis function, various factors are involved
in the development of skin barrier dysfunction. Although a previ-
ous study showed that the FLG mutations status was associated
with TEWL by the age of 3 months,10 a more recent larger-scale
study indicated no relationship between FLG mutation and TEWL
during the ﬁrst 2 days of life.11 Although we could not acquire the
FLG mutation data of all study participants, we did not detect a
signiﬁcant difference in TEWL values between FLG mutation car-
riers and non-carriers during the ﬁrst 7 days of life (TEWL values of
FLG mutation carriers vs. non-carriers, mean ± SD, 6.30 ± 1.77 vs.
8.18 ± 5.22, respectively; ManneWhitney U test; p ¼ 0.18).
We observed a statistically signiﬁcant difference in the cumu-
lative AD incidence between infants in the high and low TEWL
groups for those who received emollients only as needed. In infants
who received emollients daily, those with increased TEWL did not
have a signiﬁcantly different cumulative AD incidence than those
with low TEWL. Because it is assumed that infants in the low TEWL
group naturally have less barrier dysfunction, preventing AD in
early infancy by topically administering emollients may explain
why sustained skin barrier function is maintained.
Our data showed that noninvasive skin measurement tech-
niques, in particular measurements of TEWL on the forehead, can
contribute to identifying neonates with a high risk of developing
AD and thus may be a potential future AD prevention strategy.
Because the TEWL value can possibly increase depending on the
infant's emotional state, we performed all measurements of TEWL
while neonates were resting and not crying.Wementioned that theresults should be carefully interpreted; however, AD in infants
often develops on the face.23 Thus, it is possible that TEWL values of
the forehead are considered more useful than those of the legs.
Concerning the practical guidelines for measuring TEWL, a climate-
controlled room is recommended, if available.19 In our study, we did
not have access to such a room; hence, the relative humidity in the
room where testing was conducted was affected by the season
(data not shown). However, we observed no signiﬁcant effect of the
relative humidity on TEWL measured on the forehead (data not
shown).
A recent report showed that TEWL at 2 days or 2 months of age
predicted AD development at 1 year of age11; this is in line with our
ﬁndings. However, this study did not report on subsequent allergic
sensitization and the use of emollients. A signiﬁcant positive cor-
relation between increased TEWL and increased sensitization to
aeroallergens was found in another previous cross-sectional study.3
Eczema during infancy has been shown to be associated with the
subsequent development of bronchial asthma,24 allergic rhinitis,25
and food allergies26 called atopic march.2 This is likely caused by
eczematous sensitization. We found that infants with a high TEWL
at baseline had a higher (but not signiﬁcant) prevalence of serum
anti-ovomucoid IgE sensitization when compared to infants with a
low TEWL. TEWL in preterm neonates was shown to be higher than
that in term neonates,27 suggesting that emollient application may
be more important in premature neonates. A recent study reported
that the application of emollients in preterm neonates starting at
birth reduced the risk of infection and mortality, which supports
this notion.28 However, further studies are necessary to address the
beneﬁt of emollient application in preterm neonates.
Our study was limited by the inherent limitations of a post-hoc
analysis. Signiﬁcant differences in mean gestational agewere found
between the high and low TEWL groups at baseline. The reason for
this difference is unclear. Further randomized trials using a pro-
spective intervention study design are needed to conﬁrm the as-
sociation between TEWL measurements at birth and subsequent
Fig. 3. AD development and emollient use. In the control group, in which emollients were administered only when needed, the high TEWL group is more likely to develop AD by
age 32 weeks than the low TEWL group (A, log-rank test, p ¼ 0.016). In contrast, no signiﬁcant differences are observed between the high and low TEWL groups in the intervention
group, in which emollients were administered daily to all infants (B, log-rank test, p ¼ 0.368). AD, atopic dermatitis; TEWL, transepidermal water loss.
Table 2
Allergic sensitization at age 32 weeks between the high and low TEWL groups.
Speciﬁc IgE levels TEWL on the forehead p-value
High TEWL
group (n ¼ 53)
Low TEWL
group (n ¼ 38)
Egg white (kUA/L)
0.35 43.4% 44.7% 1.00
0.70 43.4% 39.5% 0.83
Ovomucoid (kUA/L)
0.35 18.9% 5.3% 0.07
0.70 13.2% 2.6% 0.13
IgE, immunoglobulin E; TEWL, transepidermal water loss.
K. Horimukai et al. / Allergology International 65 (2016) 103e108 107AD development. Another limitation of this study was the lack of
complete data for FLG null mutation status. The ﬁnal limitation of
our study was that only individuals with a high-risk family history
of AD were included in our analysis, implying that our ﬁndings may
not be generalizable to the general population. Although our data
need to be validated by future larger-scale prospective randomized
studies, the results of our post-hoc analysis will be useful for
developing suitable interventions for AD prevention.
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